INTRODUCTION
Microglia account for approximately 10% of the adult brain cell population and represent the first and main form of immune defense in the central nervous system (CNS; Lawson et al., 1990; Kreutzberg, 1996) . Upon CNS injury and disease, microglia become activated and they can be identified and distinguished from their resting phenotype based on a combination of morphological and immunophenotypic changes (Dheen et al., 2007; Ransohoff and Perry, 2009) . Microglia initiate immune responses by enhancing the expression of toll-like receptors (TLR) and a wide range of pro-inflammatory mediators such as tumor necrosis factor-alpha (TNFα), interleukin (IL)-1 and IL-6 for the removal of the CNS threat (Suzumura et al., 1996; Hartlage-Rübsamen et al., 1999; Bsibsi et al., 2002; Floden et al., 2005) . Microglia may also fulfill a neuroprotective role via the release of neurotrophic factors and promotion of neurogenesis for the restoration of normal physiology (Stadelmann et al., 2002) . Hence, the acute inflammatory response is generally beneficial, as it tends to minimize injury and promotes tissue repair. However, chronic neuroinflammation is closely related to various neurodegenerative disorders such as Parkinson's disease (PD), Huntington's disease (HD), Dementias, and Multiple sclerosis (MS), although the consequences of sustained microglial activation in these diseases is unclear.
Activated microglia upregulate expression of the 18-kDa translocator protein (TSPO; Chen and Guilarte, 2008; CosenzaNashat et al., 2009; Scarf et al., 2009) . TSPO are found in abundance throughout the body in peripheral organs (i.e., liver and adrenals), and hematogenous cells, but are present at very low levels in the normal healthy CNS (Banati, 2002) . Functionally, TSPO has several biological functions including the control of cholesterol transport and neurosteroid synthesis (Papadopoulos et al., 2006) , and may also be involved in the release of pro-inflammatory cytokines during inflammation (Choi et al., 2002; Wilms et al., 2003) .
Enhanced TSPO expression can be detected in vivo by using positron emission tomography (PET) imaging with the selective TSPO radioligand 11 C-PK11195 (Benavides et al., 1988; Pike et al., 1993; Banati et al., 1999) , with evidence that increases in 11 C-PK11195 binding potential (BP ND ) correspond to activation of microglia (Stephenson et al., 1995; Conway et al., 1998; Banati et al., 2000) . Although TSPO is also expressed by reactive astrocytes, a 11 C-PK11195 PET study of patients with hippocampal sclerosis, a condition histopathologically characterized by marked astrogliosis, did not yield results that were significantly different to healthy normal controls (Banati et al., 1999) . This is consistent with the view that reactive astrocytes, in vivo, do not significantly contribute to the 11 C-PK11195 signal. Therefore, in the absence of invading blood borne cells or severe focal leakage of bloodbrain barrier, the increased PK11195 binding is likely to indicate the transition of microglia from a resting to an activated state, and is due to an increase in the number, rather than the affinity, of TSPO (Banati et al., 2000) . Hence, the measurement of TSPO uptake using PET provides an in vivo tool to monitor progression and severity of neuroinflammation and is a useful indicator of active CNS disease. This article aims to review the use of PET www.frontiersin.org imaging to promote the understanding of activated microglia in neurodegenerative disease.
PARKINSON'S DISEASE AND RELATED DISORDERS
Parkinson's disease is the second most common neurodegenerative disorder of the elderly and is associated with the motor symptoms of tremor, bradykinesia, and rigidity. It is characterized by the extended loss of dopaminergic neurons in the substantia nigra pars compacta, resulting in a deficiency of dopamine in the striatum (Braak et al., 2006) , and the presence of alpha-synuclein (α-synuclein)-containing lewy bodies. PD is the most common of a group of parkinsonian movement disorders that also includes Multiple system atrophy (MSA), Corticobasal degeneration (CBD), and Progressive supranuclear palsy (PSP).
The presence of activated microglia close to dopaminergic neurons in post-mortem PD patient brains (McGeer et al., 1988a; Mogi et al., 1994; Langston et al., 1999; Imamura et al., 2003) , and PD animal models (Czlonkowska et al., 1996; Kim et al., 2009 ) suggests a close relationship between neurodegeneration and neuroinflammation in PD. Numerous investigations have proposed a deleterious role of microglial activation in PD based on the vulnerability of dopaminergic neurons to various microglia-derived pro-inflammatory cytokines (Ferrari et al., 2006; Stone et al., 2009; De Lella Ezcurra et al., 2010) , while α-synuclein can directly induce activation of microglia (Zhang et al., 2005) . However, it seems that the plasticity of microglia must be considered with regards to their contribution in PD, and their role; whether beneficial or detrimental, it may depend on the stimuli present and the stage of disease (Li et al., 2007; Michelucci et al., 2009; Sanchez-Guajardo et al., 2010) .
Further clues regarding the role of activated microglia has also come from in vivo PET imaging studies (Table 1) . Significant microglial activation, as reflected by an increase in 11 C-PK11195 BP ND was reported in the midbrain and putamen of PD patients when compared to controls, and was found to correlate positively with the motor severity of Parkinsonism (Ouchi et al., 2005; Bartels et al., 2010) . These findings suggest that activated microglia has a pathogenic importance in the disease and indicate that the early introduction of a neuroprotective drug to suppress microglial activation could be favorable in PD. Additionally, PD patients exhibited significantly increased 11 C-PK11195 BP ND in the basal ganglia, pons, and frontal and temporal cortical regions (Gerhard et al., 2006a) . In this study, the increased microglial activation remained unchanged for 2 years, while the patients deteriorated clinically during this period. Hence, it is likely that microglia are activated early in PD, where they remain activated for longer periods and possibly drive progression of the disease (Gerhard et al., 2006a) .
Multiple system atrophy is a sporadic neurodegenerative disorder involving a progressive akinetic-rigid syndrome, autonomic failure, and cerebellar dysfunction. It is associated by the appearance of abnormal glial cytoplasmic inclusions (GCI) containing (α-synuclein aggregates and neuronal loss within the nigrostriatal and olivopontocerebellar regions (Lantos and Papp, 1994) . The presence of activated microglia is also a prominent feature of MSA (Schwarz et al., 1998) . In an in vivo PET study of MSA patients, significant 11 C-PK11195 BP ND was observed in the putamen, pallidum, pons, substantia nigra pars compacta, and dorsolateral prefrontal cortex, reflecting the known distribution of neuropathological changes in MSA (Gerhard et al., 2003) . Although the role of microglia in MSA is inconclusive, microglial activation localization correlated significantly with the locations of GCIs in specific neuroanatomical systems affected in MSA (Ishizawa et al., 2004) . A correlation between extent of Frontiers in Pharmacology | Neuropharmacology microglial activation and dopaminergic neurodegeneration has also been reported (Stefanova et al., 2007) . Progressive supranuclear palsy is an adult-onset progressive neurodegenerative disease of unknown cause, characterized by PD-like symptoms such as postural instability and bradykinesia. The pathological hallmark of the disease is neurofibrillary tangles consisting of hyperphosphorylated tau, accompanied by neuronal loss in the thalamus, basal ganglia, and specific brainstem regions (Hauw et al., 1994) . Several early studies including immunohistochemical investigations have confirmed the possible involvement of activated microglia in PSP (Kida et al., 1992; Komori et al., 1998; Ishizawa et al., 2000; Ishizawa and Dickson, 2001 ). 11 C-PK11195 PET have also reported significant levels of activated microglia in brain regions known to be affected by the disease process such as the midbrain, cerebellum, pons, frontal lobe, and basal ganglia (Gerhard et al., 2006b) . Although these results were unable to support a direct causal contribution to neurodegeneration in PSP, they are at least suggestive of a role of microglia in the disease.
Corticobasal degeneration is a neurodegenerative disorder that affects both cortical and basal ganglial regions, with considerable clinical heterogeneity between patients. Typically, CBD features an asymmetric hypokinetic-rigid syndrome, coupled with alien limb phenomenon and cortical sensory impairment that is unresponsive to dopaminergic therapy (Rebeiz et al., 1968; Gibb et al., 1989) . Information on the association of activated microglia in CBD is limited, and mainly coming from immunohistochemical-based assessments (Armstrong et al., 2000; Ishizawa and Dickson, 2001 ). However, more recent in vivo PET investigations have attempted to quantify microglial activation in CBD patients. Increased 11 C-PK11195 BP ND was observed in regions such as the caudate nucleus, putamen, substantia nigra pars compacta, pons, and pre-and post central gyrus (Gerhard et al., 2004; Henkel et al., 2004 ) that correspond to the expected neuropathological changes seen in CBD (Ishizawa and Dickson, 2001; Dickson et al., 2002) . These results indicate an involvement of activated microglia in pathogenesis of CBD.
HUNTINGTON'S DISEASE
Huntington's disease is an autosomal, dominant inherited progressive neurodegenerative disorder associated with motor, cognitive, and psychiatric symptoms. It is caused by an abnormal polyglutamine-repeat expansion on the IT15 gene that codes huntingtin, and involves the progressive loss of medium spiny dopaminergic receptor-bearing striatal GABA-ergic neurons (Vonsattel and DiFiglia, 1998) . Although the role of chronic neuroinflammation in the HD pathogenesis is not fully understood, post-mortem assessments have reported high levels of activated microglia close to degenerating neurons (McGeer et al., 1988b; Messmer and Reynolds, 1998; Singhrao et al., 1999; Sapp et al., 2001) . Upregulated inflammatory cytokines have also been detected in the striatum and plasma, indicative of an inflammatory component in HD (Dalrymple et al., 2007; Björkqvist et al., 2008) .
In vivo imaging studies using 11 C-PK11195 PET have found increased microglial activation in both premanifest HD gene carriers and manifest HD patients when compared to healthy controls ( Table 2 ; Pavese et al., 2006; Tai et al., 2007; Politis et al., 2008 Politis et al., , 2011 . In premanifest HD patients, significant increases in 11 C-PK11195 BP ND in the striatum and hypothalamus was reported, which correlated inversely with neuronal dysfunction as measured by 11 C-Raclopride; a marker of dopaminergic D2/D3 receptor availability (Tai et al., 2007; Politis et al., 2008) . Interestingly, microglial activation in the striatum, and regions related to cognitive function has been shown to predict the 5-year disease clinical onset in premanifest HD patients (Tai et al., 2007; Politis et al., 2011) . These results imply that microglial activation is an early event in the HD disease course, with a possible pathogenic involvement that is associated with a subclinical progression of the disease.
In manifest HD patients, significant 11 C-PK11195 BP ND in the striatum, hypothalamus, and various cortical regions was found, that correlated with greater disease burden and higher motor disability (Pavese et al., 2006; Politis et al., 2008 Politis et al., , 2011 . The cortical www.frontiersin.org microglial activation is likely to indicate the involvement of cortical neurons in HD, a well-recognized phenomenon as the disease progresses. Collectively, these findings are consistent with the postmortem studies (Messmer and Reynolds, 1998; Sapp et al., 2001) and suggest a detrimental microglial contribution to the ongoing neuronal degeneration in HD.
DEMENTIA
Dementias are a group of disorders that are expected to affect more than 100 million people by 2050 raising remarkable financial costs for healthcare (Wimo et al., 2003) . AD is the most common cause of dementia and is the most common neurological disorder of the elderly. AD is characterized by the presence of amyloid plaques, neurofibrillary tangles, and activated microglia (for review, see Hardy and Selkoe, 2002) . There is a plethora of evidence from post-mortem human AD studies (McGeer et al., 1988a; Venneti et al., 2009 ) and animal models (Frautschy et al., 1998; Stalder et al., 1999; Leung et al., 2011) reporting a high accumulation of activated microglia in close proximity with the amyloid plaques, and upregulated levels of pro-inflammatory cytokines (Akiyama et al., 2000; Eikelenboom et al., 2002) . Positron emission tomography enables a broad range of functional processes to assess the AD brain in vivo (Table 3) . 11 C-PK11195 has been used to demonstrate increased levels of activated microglia in both AD animal models and AD patients (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011) . In AD patients, significant 11 C-PK11195 BP ND was consistently observed in the temporal, parietal, and occipital cortices, regions known to be affected by AD pathology (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011) . The increased activated microglia also inversely correlated with the patient Mini-Mental State Examination (MMSE) scores, which is compatible with a role of microglia in neuronal damage (Edison et al., 2008) . Interestingly, elevated levels of activated microglia were also detected in patients with amnestic mild cognitive impairment (MCI; Okello et al., 2009a) , although this was not observed in another study assessing MCI patients . MCI could represent an early precursor stage of AD, since it was found that MCI patients with increased amyloid load were significantly more likely to clinically convert to AD within 3 years (Okello et al., 2009b) . Therefore, microglial activation could be an early event in the AD pathogenesis that begins at the MCI stage.
Despite the evidence suggestive of a pathogenic role of activated microglia in AD, it is hypothesized that the accumulation of amyloid plaques is actually due to a failure in microglial clearance mechanisms that would normally remove the protein (Bornemann et al., 2001; DiCarlo et al., 2001; Napoli and Neumann, 2009 ). This indicates a beneficial, rather than detrimental role of microglia in AD. Notwithstanding the abundance of activated microglia close to senile plaques, they maybe inefficient in the clearance of amyloid, hence, resulting in aggregate formation (Bolmont et al., 2008) . It has been shown that in the presence of pro-inflammatory cytokines, phagocytic functions of microglia are compromised (Koenigsknecht-Talboo and Landreth, 2005) . Therefore, microglia may confer a dichotomous role in AD, where early microglial activation is possibly neuroprotective involving the removal of amyloid. However, chronic neuroinflammation may downregulate amyloid clearance mechanisms, thus, promoting aggregation and progression of disease.
Frontotemporal lobar degeneration (FTLD) which includes frontotemporal dementia is the name given to a group of pathologically, clinically, and genetically heterogeneous disorders involving focal atrophy of the frontal and temporal lobes, while unlike AD, with sparing of the parietal and occipital regions (Neary et al., 1998) . Another important dissimilarity between AD and FTLD pathology is the absence of amyloid plaque formation (Paulus et al., 1993; Mirra and Hyman, 2002) . Rather, the key histopathological features of FTLD, depending on subtype, Frontiers in Pharmacology | Neuropharmacology includes tau deposition (including Pick bodies) and ubiquitinpositive, tau-negative inclusions (Munoz et al., 2003; Uchihara et al., 2003) . In vivo PET imaging of FTLD patients detected enhanced microglial activation in the expected frontotemporal regions (Cagnin et al., 2004) . In the same study, significant 11 C-PK11195 BP ND in the bilateral putamen is also consistent with previous neuropathological data showing the involvement of the basal ganglia in FTLD (Mirra and Hyman, 2002) . These observations indicate the presence of an active microglial response that reflects progressive neuronal degeneration. Importantly, the detection of increased microglial activation in affected regions in FTLD suggests that microglial responses occur independently of amyloid deposition, and that neuronal loss alone is enough to induce activation (Cagnin et al., 2004) . However, whether this applies to AD pathogenesis requires further investigation.
MULTIPLE SCLEROSIS
Multiple sclerosis is a disease characterized pathologically by inflammatory demyelination and axonal transection, and is the most common cause of non-traumatic disability in young adults (Compston and Coles, 2008) . The involvement of activated microglia has long been proposed in MS (Benveniste, 1997) . Post-mortem investigations have detected activated microglia in the cortical GM of MS patients (De Groot et al., 2001; Peterson et al., 2001; Petzold et al., 2002) , while histopathological studies have implicated microglia in lesion pathogenesis (for review, see Lassmann, 2008 ). An observed correlation between neuronal loss and microglial activation was reported in animal experimental MS (Rasmussen et al., 2007) . Significant levels of activated microglia was also found in MS patients, especially in the progressive forms of disease that are associated with neurodegeneration (Kutzelnigg et al., 2005; Magliozzi et al., 2010) , and selective ablation of parenchymal microglia was able to prevent demyelination and axonal damage (Heppner et al., 2005) .
Pathological aspects of MS such as neuroinflammation, demyelination, and neurodegeneration may be explored in vivo with PET (for review, see Kiferle et al., 2011) . PET with 11 C-PK11195 and other tracers has demonstrated inflammatory processes with microglial involvement in MS (Figure 1; Table 4 ). In animal experimental MS and human post-mortem brains it has been shown that 11 C-PK11195 uptake corresponds to the distribution pattern of activated microglia (Banati et al., 2000) . It has also been demonstrated that there is increased 11 C-PK11195 BP ND in areas of focal pathology identified by T1-and T2-weighted MRI (Vowinckel et al., 1997; Banati et al., 2000) and in gadoliniumenhanced T1-weighted MRI (Debruyne et al., 2003) . Increased 11 C-PK11195 BP ND was observed in normal-appearing gray and white anatomical structures (Banati et al., 2000; Debruyne et al., 2003; Versijpt et al., 2005) . This is in line with the hypothesis that inflammatory processes initiated by microglia early in MS may constitute the real burden of disease, associated with invisible microglia-mediated damage that occur independently of relapses (Kesselring, 1990; Confavreux et al., 2000) . A positive correlation has been suggested between ligand uptake and disease duration, disability, and brain atrophy (Banati et al., 2000; Debruyne et al., 2003; Versijpt et al., 2005) , although the correlations were not consistently replicated across the different studies. However, recent data from our group found a significant association between high 11 C-PK11195 BP ND in the cortical gray matter and disability in patients with secondary progressive MS, and with higher 11 C-PK11195 BP ND in the secondary progressive group than the relapse-remitting MS group (Politis et al., in press ). These findings are consistent with a detrimental role of microglia in MS. Enhanced microglial activation in MS has also been detected using the more recently developed TSPO tracers 11 C-vinpocetine and 11 C-PBR28 (Vas et al., 2008; Oh et al., 2011) .
Microglial activation may contribute to the mechanism of axonal injury via the release of soluble factors that may either directly or indirectly cause neuronal dysfunction (Peterson et al., 2001; Barnett and Prineas, 2004; Dutta and Trapp, 2006; Zipp et al., 2006; Dal Bianco et al., 2008; Lassmann, 2008; Magliozzi et al., 2010) , and consequently result in progressive increase in impairment and disability. However, activated microglia may also exert protective functions with MS through the release of neurotrophic factors (Stadelmann et al., 2002; Napoli and Neumann, 2009) , and triggering of remyelination mechanisms Setzu et al., 2006) . This suggests a possible dichromatic role of microglia in MS.
NEW TSPO LIGANDS
11 C-PK11195 was the first tracer to be consistently used for the study of activated microglia and neuroinflammation in vivo. However, limitations associated with the application of 11 C-PK11195 include a high level of non-specific binding (Petit-Taboué et al., 1991) , and a poor signal to noise ratio, which complicates its quantification (Boutin et al., 2007) . This has prompted the search for novel PET tracers (termed, second generation radioligands) with improved capacities to quantify TSPO expression.
Radioligands such as 11 C-PBR28, 11 C-DAA1106, 18 F-FEDAA1106, and 18 F-PBR111 have recently been developed to image TSPO in vivo (Gulyás et al., 2002; Ikoma et al., 2007; Fujita et al., 2008; Vas et al., 2008; Yasuno et al., 2008; Oh et al., 2011 ; for a review, see Chauveau et al., 2008) . Published data using the second generation ligands 11 C-DAA1106 (Ikoma et al., 2007) and www.frontiersin.org 18 F-FEDAA1106 (Fujimura et al., 2006) in humans were promising, with both tracers showing significantly higher cerebral uptake than 11 C-PK11195. Furthermore, increased 11 C-DAA1106 binding was reported in AD patients (Yasuno et al., 2008) that were similar to the previous studies that used 11 C-PK11195 (Cagnin et al., 2001 ). The only published study using the second generation radioligand 11 C-PBR28 found areas of focal increases in radiotracer binding in the brain of MS patients (Oh et al., 2011) . Interestingly, the increased focal 11 C-PBR28 binding preceded the development of some gadolinium-enhancing lesions. Brain parenchymal 11 C-PBR28 binding in MS patients was positively correlated with the duration of the disease, however it was not significantly higher than that of healthy volunteers. Interpretation of these results is limited by the lack of characterization of the binding affinity pattern, which might have significantly affected the comparison between subjects.
It has been recently demonstrated that there are three different affinity patterns for second generation TSPO ligands in healthy volunteers as well as patients with MS, which was evident with all the ligands tested ( 11 C-PBR28; 11 C-PBR06; 18 F-PBR111; Owen et al., 2010) . This presents a methodological problem, as differences in PET signal across subjects cannot be safely interpreted as differences in target density, but may reflect differences in the affinity pattern. A possible approach to solve this problem is based on the use of peripheral binding affinity, which can be characterized to classify subjects into one of the groups, as differences in affinity status between individuals have been shown to be present on peripheral cells as well (Owen et al., 2010) . Interestingly, the difference in binding patterns observed with second generation radioligands was not observed with 11 C-PK11195. Also, in vitro autoradiography data using 11 C-PK11195 suggest a receptor density (B MAX ) significantly higher than that found using second generation ligands. It could be speculated that 11 C-PK11195 and newer ligands bind to distinct sites within the TSPO molecule.
Although, data obtained from first generation studies have been promising and suggested that 11 C-PK11195 could be useful to image acute inflammatory lesions and microglial activation in MS, a conclusive demonstration of the potential of TSPO imaging for the application as disease biomarker, indicative of microglial activation in MS, is still lacking. Furthermore, despite second generation ligands constituting a potential improvement relative to 11 C-PK11195 at least from a methodological point of view, a clear advantage in their clinical application as disease biomarkers has not been demonstrated yet.
For these reasons, we aim to characterize a second generation TSPO PET radioligand in vivo in humans, and to evaluate its application as a disease biomarker in MS.
Among second generation TSPO tracers, 18 F-PBR111 presents different advantages, as there is low difference in its affinity for TSPO between high, medium, low affinity binders. Also, it could be potentially used in clinical applications as it is labeled with fluorine-18. Promising preclinical data, and ongoing studies in neurological patients, suggest it could be a good choice amongst second generation TSPO ligands to progress into studies in MS patients.
CONCLUSION
Inflammation coupled with the presence of activated microglia seems to be a common feature of a wide range of CNS diseases. However, despite a large number of research studies, the exact role of microglia in chronic neurodegenerative diseases remains uncertain. In line with the high plasticity of microglia that allows them to perform numerous CNS functions, microglia are likely to Frontiers in Pharmacology | Neuropharmacology play a dichromatic role in disease, depending on signals present in their microenvironment and the duration of activation. While early microglial activation could represents a beneficial response (i.e., removal of CNS threat, promoting tissue repair and removal of misfolded protein), chronic exposure could induces detrimental effects by promoting neuronal death (i.e., through the sustained release of neurotoxic factors), thus, contributing to progression of disease. PET imaging with the use of TSPO radioligands provides a valuable tool that allows us to track the progression and severity of neuroinflammation in the living brain, and is a useful indicator of active CNS disease. Therefore, the early detection of microglia using PET could offer opportunities for pharmacological interventions to limit the potential disruptive effects of chronic microglial activation. Furthermore, with the development of newer TSPO tracers, the potential for PET imaging research to promote our understanding of activated microglia in CNS disease can only increase.
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